BioStock has published the article: “Ultimovacs initiates fourth phase II trial with UV1”

“Christmas came a few days early for Ultimovacs as the company was able to announce the initiation of its fourth phase II trial with universal vaccine UV1. The combination study, aimed at head and neck cancer patients indicated to receive checkpoint inhibitor pembrolizumab, will be conducted at 10 sites across Germany and led by renowned principal investigator Prof. Mascha Binder, M.D.”Read the full article here

About BioStock
BioStock is a leading Nordic digital news and analytics service focusing exclusively on the life science sector.